 |
News releases
Please be advised that the information posted was accurate at the time of posting, but may be superseded by subsequent news releases.
To automatically receive future news releases, please go to the News
subscription service page.
2010
- [2009]
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
(click to view the full text)
|
December 18, 2009
Æterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia |
December 16, 2009
Æterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma |
December 9, 2009
Æterna Zentaris Announces Appointment of New Board Member |
December 7, 2009
Æterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the
51st Annual Meeting of the American Society of Hematology
|
December 7, 2009
Æterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia |
December 2, 2009
Æterna Zentaris’ Anti-Cancer Compound, Perifosine
(KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma |
November 24, 2009
Æterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer |
November 11, 2009
Æterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine (KRX-0401) at 51st Annual Meeting of the American Society of Hematology |
November 11, 2009
Æterna Zentaris Reports Third Quarter 2009 Financial and Operating Results |
November 9, 2009
Æterna Zentaris: Scientific Article Supports Perifosine’s Development in Kidney Cancer |
November 4, 2009
Æterna Zentaris to Announce Third Quarter 2009 Financial and Operating Results on November 11, 2009 |
November 2, 2009
Æterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS 108 in Ovarian Cancer |
October 23, 2009
Æterna Zentaris Receives US$5.5 Million from Institutional Investors |
October 19, 2009
Æterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share |
October 19, 2009
Æterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test
for Growth Hormone Deficiency |
October 1, 2009
Æterna Zentaris to Present at BioContact in Quebec City
on October 8 |
September 30, 2009
Æterna Zentaris: Thorough QT Trial with Cetrorelix in Benign Prostatic Hyperplasia Meets Primary Endpoint |
September 29, 2009
Æterna Zentaris Partner, Keryx, Presented Updated Phase 2 Data on Perifosine (KRX-0401) for the Treatment of Advanced Metastatic Renal Cell Carcinoma at 8th International Kidney Cancer Symposium in Chicago. |
September 21, 2009
Æterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer |
September 16, 2009
Æterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma |
September 1, 2009
Æterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference |
August 17, 2009
Æterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia |
August 11, 2009
Æterna Zentaris Reports Second Quarter 2009 Financial and Operating Results |
August 6, 2009
Æterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference |
August 5, 2009
Æterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009 |
August 3, 2009
Æterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma |
July 7, 2009
Æterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction |
June 24, 2009
Æterna Zentaris Receives US$10 Million from Institutional Investors |
June 19, 2009
Æterna Zentaris to Raise US$10 Million from Institutional Investors at US$1.88 Per Share |
June 15, 2009
Æterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule |
June 10, 2009
Æterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia |
June 8, 2009
Æterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non Small Cell Lung Cancer |
June 8, 2009
Æterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130 |
June 1, 2009
Æterna Zentaris Partner Keryx Reports Positive Phase 2 Data for Perifosine (KRX-0401) in Colon and Kidney Cancer at ASCO Meeting
|
June 1, 2009
Æterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting |
May 19, 2009
Æterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting |
May 6, 2009
Æterna Zentaris Reports First Quarter 2009 Financial and Operating Results |
April 30, 2009
Æterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009 |
April 29, 2009
Æterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement |
April 22, 2009
Æterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver |
April 21, 2009
Æterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting |
April 15, 2009
Æterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting |
March 11, 2009
Æterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results |
March 6, 2009
Æterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009 |
March 6, 2009
Æterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia |
 |
 |
